Evidence map›Paper›PMID 36315510›Full record

ArticlePloS one2022

5-ethyl-2'-deoxyuridine fragilizes Klebsiella pneumoniae outer wall and facilitates intracellular killing by phagocytic cells.

Estelle Ifrid, Hajer Ouertatani-Sakouhi, Tania Jauslin, Sebastien Kicka, Gianpaolo Chiriano, Christopher F Harrison, Hubert Hilbi, Leonardo Scapozza, Thierry Soldati, Pierre Cosson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Estelle IfridDepartment of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Centre Médical Universitaire, Geneva, Switzerland.
Hajer Ouertatani-SakouhiDepartment of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Centre Médical Universitaire, Geneva, Switzerland.
Tania JauslinDepartment of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Centre Médical Universitaire, Geneva, Switzerland.
Sebastien KickaDepartment of Biochemistry, Faculty of Science, University of Geneva, Geneva, Switzerland.
Gianpaolo ChirianoPharmaceutical Biochemistry, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Christopher F HarrisonMax von Pettenkofer Institute, Department of Medicine, Ludwig-Maximilians University Munich, Munich, Germany.
Hubert HilbiInstitute of Medical Microbiology, Department of Medicine, University of Zürich, Zürich, Switzerland.
Leonardo ScapozzaPharmaceutical Biochemistry, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.ORCID 0000-0003-1079-648X
Thierry SoldatiDepartment of Biochemistry, Faculty of Science, University of Geneva, Geneva, Switzerland.
Pierre CossonDepartment of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Centre Médical Universitaire, Geneva, Switzerland.ORCID 0000-0002-4881-0358
University of Geneva · CHLudwig-Maximilians-Universität München · DEUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Klebsiella pneumoniae is the causative agent of a variety of severe infections. Many K. pneumoniae strains are resistant to multiple antibiotics, and this situation creates a need for new antibacterial molecules. K. pneumoniae pathogenicity relies largely on its ability to escape phagocytosis and intracellular killing by phagocytic cells. Interfering with these escape mechanisms may allow to decrease bacterial virulence and to combat infections. In this study, we used Dictyostelium discoideum as a model phagocyte to screen a collection of 1,099 chemical compounds. Phg1A KO D. discoideum cells cannot feed upon K. pneumoniae bacteria, unless bacteria bear mutations decreasing their virulence. We identified 3 non-antibiotic compounds that restored growth of phg1A KO cells on K. pneumoniae, and we characterized the mode of action of one of them, 5-ethyl-2'-deoxyuridine (K2). K2-treated bacteria were more rapidly killed in D. discoideum phagosomes than non-treated bacteria. They were more sensitive to polymyxin and their outer membrane was more accessible to a hydrophobic fluorescent probe. These results suggest that K2 acts by rendering the membrane of K. pneumoniae accessible to antibacterial effectors. K2 was effective on three different K. pneumoniae strains, and acted at concentrations as low as 3 μM. K2 has previously been used to treat viral infections but its precise molecular mechanism of action in K. pneumoniae remains to be determined.

Indexed as

DictyosteliumKlebsiella InfectionsAnti-Bacterial AgentsDeoxyuridineHumansKlebsiella pneumoniaePhagocytesAnti-Bacterial AgentsDeoxyuridineedoxudin

Identifiers

PMID36315510
PMCPMC9621411
OpenAlexW4307699475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.